MicroDiPeptide229

MicroDiPeptide229 (MDP229) is a microbiome-derived therapeutic peptide developed by Microbiotica for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis. Discovered using Microbiotica's proprietary platform, which identifies specific bacterial signatures linked to clinical outcomes, MDP229 is designed to mimic the beneficial effects of the gut microbiota on the host immune system. The peptide functions by modulating immune responses, potentially through the induction of regulatory T cells (Tregs) or the activation of anti-inflammatory pathways such as IL-10 signaling, thereby promoting mucosal healing and reducing intestinal inflammation. As a peptide-based approach to microbiome therapy, it offers a more targeted and potentially safer alternative to whole-consortium live biotherapeutic products.

Other names

MicroDiPeptide 229MicroDiPeptide229MicroDiPeptide-229